Vote Scores
Filings read through

How funds voted at Spero Therapeutics, Inc.

Ticker
SPRO
SEC company number
1701108
Filers reporting
67, year to 30 June 2026
Latest meeting on file
Meetings on file
4

In the year to 30 June 2026, 67 filers on Form N-PX reported votes at Spero Therapeutics, Inc.. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 114 marks to the ballot items, each with or against management. 88.6% of the marks are with management.

On say-on-pay, 3 of the 61 reporting filers that marked the item voted against management. This is 4.9% of the filers. Of the reported shares, 0.4% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

At the meeting of 23 Jun 2026, 13 fund families have a say-on-pay position with management and 1 has a position against management.

By filers reporting in the year to 30 June 2026, Spero Therapeutics, Inc. was number 4,488 of 11,972 companies with a page and votes in that year. The number of filers reporting at Spero Therapeutics, Inc. rose by 42.6% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category SECTION 14A SAY-ON-PAY VOTES is 47.2% of the vote records at Spero Therapeutics, Inc.. At all companies on this site, it is 12.3%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 23 Jun 2026

67 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    2 nominees. 66.0% of the reported votes are for. 8 filers withheld from or voted against at least one nominee.

    46 vote records from 13 filers. 1 of the 13 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 4
    • Abstain or withhold 1
    • Split or no vote 4
    • Against management 1
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    86 vote records from 66 filers. 3 of the 61 filers that marked the item voted against management. 5 filers gave no management mark.

    • Positions of 14 fund families
    • For 13
    • Against 1
    • Against management 1
  3. Item 3: Audit-related items (auditor ratification)

    23 vote records from 13 filers. 0 of the 13 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 9
  4. Item 4: CAPITAL STRUCTURE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    23 vote records from 13 filers. 0 of the 13 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 9
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    26 vote records from 14 filers. 9 of the 14 filers that marked the item voted against management.

    • Positions of 9 fund families
    • For 3
    • Against 6
    • Against management 6

Positions of the fund families at the meeting of 23 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Spero Therapeutics, Inc., meeting of 23 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
American CenturyAgainst, against management
BlackRock and iSharesFor
BNY MellonFor
Charles SchwabFor
DimensionalFor
FidelityFor
Guggenheim and RydexFor
InvescoFor
Morgan Stanley, Eaton Vance and CalvertFor
Northern Trust and FlexSharesFor
PGIM and PrudentialFor
State Street and SPDRFor
VanguardFor
Victory CapitalFor

Every meeting on file

Meetings of Spero Therapeutics, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 20266754.9%
year to 30 June 20254742.4%
year to 30 June 20246748.1%
year to 30 June 202475715.9%

Say-on-pay, season by season

Say-on-pay at Spero Therapeutics, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 2026674.9%0.4%
year to 30 June 2025472.4%0.1%
year to 30 June 20249115.9%5.2%
Spero Therapeutics, Inc. and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management4.9%6.6%
Reported shares against management0.4%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Spero Therapeutics, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS20925.2%
SECTION 14A SAY-ON-PAY VOTES39247.2%
AUDIT-RELATED779.3%
SHAREHOLDER RIGHTS AND DEFENSES182.2%
CAPITAL STRUCTURE232.8%
COMPENSATION8710.5%
CORPORATE GOVERNANCE242.9%

The record at the SEC

Each link loaded on .

Cite this page

Vote Scores. How funds voted at Spero Therapeutics, Inc.. https://votescores.com/company/spero-therapeutics-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Spero Therapeutics, Inc. are on file?
4 meetings are on file, from 5 Oct 2023 to 23 Jun 2026. 4 meetings have 20 or more reporting filers and have their own page.
Did filers report proposals from security holders at Spero Therapeutics, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Spero Therapeutics, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Spero Therapeutics, Inc., grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .